Eli Lilly and Co.

Lilly suffers another bruise from Novo

March 9, 2011
J.K. Wall
The failure of its drug Bydureon to match the performance of Novo’s Victoza trims but doesn’t kill sales prospects for the highly touted diabetes drug.
More

Lilly's Bydureon falls short of competitor in study

March 3, 2011
Bloomberg News
Bydureon, the diabetes drug being developed by Amylin Pharmaceuticals Inc., Eli Lilly and Co. and Alkermes Inc., didn’t control the disease better than Novo Nordisk A/S’s Victoza in a study.
More

UPDATE: Bioanalytical researcher opening lab in Indianapolis

March 1, 2011
Advion BioServices is expected to open the lab at Purdue Research Park in Indianapolis in May with 49 employees. Some of the workers may come from Eli Lilly and Co., which is moving its drug-discovery bioanalytical operations to Advion as part of a partnership.
More

North of South development to start this summer

March 1, 2011
Tom Harton
Now that financing for Buckingham Cos.’ massive project has the city’s blessing, the local developer is turning its full attention to construction of the 14-acre, mixed-use complex.
More

Eli Lilly neuroscience chief resigns

February 25, 2011
J.K. Wall
David Bredt, vice president of neuroscience research, has resigned “to pursue other opportunities,” according to Lilly spokeswoman Judy Kay Moore. Bredt had overseen Lilly’s development of various drugs, including molecules in late-stage human testing to treat Alzheimer’s and depression.
More

UPDATE: Lilly settles pollution suit for $337,500

February 24, 2011
Scott Olson
A complaint filed Wednesday by the U.S. government says Lilly's plant on South Harding Street is emitting high levels of acetonitrile and methanol, considered hazardous air pollutants by the EPA.
More

Lilly looks to double pipeline size again

February 23, 2011
J.K. Wall
Indianapolis-based Lilly is developing what it calls “The Mirror Portfolio,” which it expects to grow to 45 to 60 drugs in five years. This month, Lilly announced it had secured venture-capital funding for the first two drugs in this alternative pipeline.
More

Emerging markets give Lilly hope in patent crunch

February 19, 2011
J.K. Wall
In a kind of alternate drug universe, sales of Eli Lilly and Co.’s ghosts of blockbusters past are soaring in China—prompting the drugmaker to pour money into emerging markets in an attempt to prop up revenue.
More

Lilly takeover provision to be voted on again

February 11, 2011
Scott Olson
The effort to remove an 80-percent approval threshold for takeover bids against the wishes of Lilly's board is on the agenda of the company's April 18 annual meeting.
More

Lilly names new head of cancer drug business

February 11, 2011
Associated Press
Eli Lilly and Co. on Friday named company insider Sue Mahony as president of its cancer drug business.
More

Recent successes don't change Lilly's outlook

February 9, 2011
J.K. Wall
Eli Lilly and Co. can be credited with using acquisitions to unclog its product pipeline. It launched two drugs in the past 18 months, won market approval for a third and will likely get nods for two more drugs this year. Trouble is, they all have paltry sales prospects.
More

Lilly collaboration with outside researchers yields first deal

February 8, 2011
Chris O'Malley
Eli Lilly and Co.'s PD2 project attracted 30,000 compounds from researchers in 26 countries. And Lilly scientist Alan Palkowitz said it's just the first of many such collaborations.
More

Technicality delays council's North of South vote

February 8, 2011
Tom Harton
A technicality caused the City-County Council on Monday night to put off a final vote on the massive North of South mixed-use project slated to be built on 14 acres north of the Eli Lilly and Co. corporate campus.
More

Struggling Lilly turns to antidepressant Cymbalta for lift

February 5, 2011
Greg Andrews
Cymbalta racked up $3.5 billion in sales last year, and some analysts say it may approach $5 billion before generic competition arrives in 2013.
More

2010 compensation fell about 20 percent for top Lilly execs

February 4, 2011
J.K. Wall
Compensation for Eli Lilly and Co.’s top executives fell last year due to a change to its stock award program and as the company struggled to bring new medicines to market.
More

Lilly, Bristol-Myers halt enrollment in lung-cancer trial

February 2, 2011
J.K. Wall
Eli Lilly and Co. and Bristol-Myers Squibb Co. stopped enrolling new patients in a clinical trial of an experimental lung cancer drug over concerns about patients developing blood clots.
More

Potential competitor to Lilly drug shows promise in study

February 2, 2011
 IBJ Staff and Bloomberg News
Sanofi-Aventis's experimental diabetes drug lixisenatide, given to volunteer patients once a day, was at least as effective as Eli Lilly and Co. and Amylin Pharmaceuticals Inc.'s twice-daily medicine Byetta, a study found.
More

Lilly's fourth-quarter profit surges, topping analysts' predictions

January 27, 2011
J.K. Wall
The Indianapolis-based drugmaker earned $1.2 billion in the quarter, compared with $915 million in the same period a year ago. Profit per share beat Wall Street forecasts by a penny.
More

Lilly product gets boost; Wall Street yawns

January 26, 2011
J.K. Wall
Eli Lilly and Co. probably will get approval for its newly acquired imaging agent used to diagnose Alzheimer’s disease, but so far analysts are unimpressed.
More

Head of Lilly's oncology unit resigning

January 25, 2011
John H. Johnson has been hired as CEO by East Brunswick, N.J.-based biotechnology company Savient Pharmaceuticals Inc.
More

Vanderbilt rejected by high court on Cialis patents

January 24, 2011
Bloomberg News
Supreme Court justices on Monday left intact a ruling throwing out a lawsuit pressed by the Nashville, Tenn., university against Eli Lilly's Icos subsidiary.
More

Indiana companies prepping for burst of acquisitions

January 22, 2011
Francesca Jarosz
Conditions are ripe for a barrage of mergers and acquisitions to take place this year.
More

Lilly imaging drug fails to win FDA panel's backing

January 21, 2011
Bloomberg News
Eli Lilly and Co.'s Amyvid isn't ready to be approved to detect Alzheimer's-related deposits in the brain, according to FDA advisors. The medicine could still be approved if Lilly establishes a training program and a way to ensure that the results of brain scans are read consistently, they said.
More

DeCoudreaux leaving Lilly for top job at Mills College

January 20, 2011
J.K. Wall
Alecia DeCoudreaux, the top attorney for Eli Lilly and Co.’s U.S. unit and an active community volunteer, will leave to become president of Mills College in California on July 1.
More

Down on luck, Lilly finds comfort in pets

January 19, 2011
J.K. Wall
Eli Lilly and Co. continues to misfire on getting new human medicines approved, but its animal health unit is on a roll.
More
Page  << 11 12 13 14 15 16 17 18 19 20 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT